Clinical Report: Assessment of Polygenic Risk Scores for Breast Cancer in High-Risk African American Women

Overview

This study evaluates the performance of newly developed polygenic risk score (PRS) models for breast cancer (BC) in a cohort of African American women with a strong family history of cancer.

Background

Breast cancer remains a leading cause of cancer-related mortality among women, with significant disparities in survival rates between African American women and their European counterparts. The aggressive nature of triple-negative breast cancer, which disproportionately affects women of African ancestry, highlights the need for improved risk assessment tools. Polygenic risk scores (PRSs) represent a promising approach to enhance risk stratification and inform screening strategies.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• The study focused on African American women aged 18-89 with negative results for pathogenic variants in breast cancer susceptibility genes.
• PRS models demonstrated strong predictive performance in independent cohorts of individuals with African ancestry.
• Validation of PRS models is crucial for assessing their accuracy in high-risk populations.
• Women in the highest PRS percentiles may have lifetime risks comparable to those reported for carriers of pathogenic variants in moderate-penetrance genes.
• Current BC screening primarily relies on age and family history.

Clinical Implications

The findings suggest that PRS could enhance risk assessment for breast cancer in high-risk African American women, potentially guiding more personalized screening strategies. Further validation in diverse populations is necessary to confirm these models' applicability in clinical settings.

Conclusion

The study underscores the importance of validating polygenic risk scores in high-risk populations to improve breast cancer risk stratification and screening. Continued research is needed to integrate these tools into clinical practice effectively.

Related Resources & Content

1. Gao et al., Journal of Clinical Oncology, 2021 -- Effect of Polygenic Risk Score on Estimated Breast Cancer Risk Among Carriers of Pathogenic Variants in Predisposition Genes
2. Conexiant, 2023 -- Diabetes Risk Scores: Beyond Glucose
3. The ASCO Post, 2025 -- Breast Cancer: Genome-Wide Study Identifies Two New Risk Genes in Black South African Women
4. NCCN Guidelines® Insights, 2026 -- Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026
5. JAMA Network, 2026 -- Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial
6. the asco post — Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score
7. Clinical implementation of polygenic risk scores | European Journal of Human Genetics
8. Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry - PubMed
9. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026 - PubMed
10. How do I enter Polygenic Risk Scores manually using the CanRisk Tool?” - CanRisk Knowledgebase - Confluence
11. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial | Trials | JAMA | JAMA Network
12. Full article: Women’s experiences of risk-stratified breast cancer screening in the MyPeBS trial: a qualitative comparative study across two European countries
13. Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction | Nature Genetics
14. Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women - PMC